Editor’s Note: The following was written on behalf of the IASLC Staging and Prognostic Factors Committee. The IASLC Staging and Prognostic Factors Committee (SPFC) proposed revisions to the lung cancer […] Read more

By Vassiliki Papadimitrakopoulou, MD Posted: June 2018 The Lung Master Protocol Trial (Lung-MAP) was designed in 2014 as a phase II/III trial overseen by a private–public collaboration among institutions participating […] Read more

By Anna Farago, MD, PhD Posted: June 2018 Small cell lung cancer (SCLC) accounts for approximately 15% of all new lung cancer diagnoses in the United States. Approximately 30% of […] Read more

Biosimilars have proven themselves to the U.S. FDA, but clinicians are still wary. By Leah K. Lawrence Posted: June 2018 Healthcare providers are more than familiar with the use of […] Read more

By Tiziana Vavalà, MD, andSilvia Novello, MD, PhD Posted: April 2018 Approximately 1.8 million new lung cancer cases worldwide are diagnosed annually, and 85% of these cases are NSCLC. Only […] Read more

By Annemie Snoeckx, MD, andPaul E. Van Schil, MD, PhD Posted: April 2018 No universally accepted guidelines or management protocols exist for diagnosis and treatment of screen-detected nodules. Radiologic management […] Read more

Availability of next-generation sequencing continues to improve, but current technology cannot speed turnaround time of results. Posted: February 2018 The standard of care for all patients diagnosed with advanced nonsquamous […] Read more

Posted: December 2017 Experts in molecular testing discussed various issues on this topic in October at the IASLC 18th WCLC. Neal Lindeman, MD, led off the session with an overview […] Read more

By Christian Rolfo, MD, PhD, MBAh, and Philip C. Mack, PhD Posted: December 2017 In just the past decade, tremendous advancements in the treatment of metastatic non-small cell lung cancer […] Read more

By Jason K. Molitoris, MD, PhD, Anthony D. Nehlsen, MD, and Minesh P. Mehta, MD Posted: October 2017 Up to 40% of patients with advanced non-small cell lung cancer (NSCLC) […] Read more